Robeco Institutional Asset Management B.V. Has $130.07 Million Stock Holdings in Stryker Corporation $SYK

Key Points

• Robeco Institutional Asset Management B.V. increased its holdings in Stryker Corporation by 2.3%, owning approximately $130.07 million in stock, according to the latest SEC filing.
• Stryker's recent earnings report showed $3.13 earnings per share for the quarter, exceeding analysts' expectations of $3.07, with revenue rising 11.1% year-over-year.
• Insider selling activity included Director Ronda E. Stryker selling 200,000 shares at an average price of $376.45, resulting in a transaction worth over $75 million.

Robeco Institutional Asset Management B.V. lifted its stake in Stryker Corporation (NYSE:SYK - Free Report) by 2.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 328,764 shares of the medical technology company's stock after acquiring an additional 7,517 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.09% of Stryker worth $130,069,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Goodman Advisory Group LLC bought a new stake in shares of Stryker during the first quarter valued at approximately $32,000. City Holding Co. increased its holdings in Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after buying an additional 74 shares during the period. Ridgewood Investments LLC raised its stake in shares of Stryker by 48.4% in the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company's stock valued at $36,000 after buying an additional 30 shares in the last quarter. Ransom Advisory Ltd bought a new position in shares of Stryker during the 1st quarter worth about $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in shares of Stryker during the 1st quarter valued at about $40,000. Institutional investors own 77.09% of the company's stock.

Stryker Trading Up 0.6%

Shares of SYK opened at $366.50 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The company has a market cap of $140.12 billion, a price-to-earnings ratio of 48.54, a PEG ratio of 2.62 and a beta of 0.94. The stock has a fifty day moving average price of $383.47 and a two-hundred day moving average price of $378.96. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. During the same period last year, the company posted $2.81 earnings per share. The firm's quarterly revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker's payout ratio is currently 44.50%.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Viju Menon sold 500 shares of the firm's stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares of the company's stock, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on SYK shares. Wall Street Zen lowered shares of Stryker from a "buy" rating to a "hold" rating in a research report on Friday, September 26th. Wells Fargo & Company increased their target price on Stryker from $435.00 to $445.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Rothschild & Co Redburn began coverage on Stryker in a research report on Thursday, September 18th. They set a "neutral" rating and a $420.00 target price for the company. Truist Financial set a $415.00 price target on Stryker and gave the company a "hold" rating in a research report on Monday, August 4th. Finally, Evercore ISI lifted their price objective on Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. Fourteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $430.33.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.